Marta Celorrio Navarro

Medicine & Life Sciences

1. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine 87%
2. 4-(3-3,4-p-menthadien-(1,8)-yl)olivetol 54%
3. 4-phenyl-1,2,3,6-tetrahydropyridine 34%
4. Acetylcysteine 31%
5. AMPA Receptors 32%
6. Animal Models 23%
7. Animals 31%
8. Brain 27%
9. Brain Injuries 53%
10. Cannabidiol 26%
11. Cannabinoid Receptor CB1 44%
12. Cannabinoid Receptor CB2 48%
13. Cannabinoid Receptors 26%
14. Cannabinoids 21%
15. Cannabis 29%
16. cyclohexyl carbamic acid 3'-carbamoylbiphenyl-3-yl ester 34%
17. Dopamine 23%
18. Dopamine D3 Receptors 39%
19. Dronabinol 22%
20. Dysbiosis 34%
21. Endocannabinoids 78%
22. Facial Nerve 30%
23. Facial Paralysis 32%
24. fatty-acid amide hydrolase 41%
25. Globus Pallidus 37%
26. Glutamate Receptors 30%
27. glyceryl 2-arachidonate 19%
28. Hypoxia 43%
29. JZL 184 100%
30. Keratinocytes 26%
31. Mandibular Nerve 36%
32. Microglia 22%
33. Minocycline 34%
34. Monoacylglycerol Lipases 83%
35. N-(4-(4-(2,3-dichlorophenyl)piperazin-1-yl)but-2-enyl)-4-pyridine-2-ylbenzamide 57%
36. Neurogenesis 29%
37. Neuroglia 48%
38. Neuronal Plasticity 26%
39. Neurons 19%
40. Neuroprotection 26%
41. Neuroprotective Agents 39%
42. Parkinson Disease 94%
43. Parvalbumins 35%
44. Phenotype 30%
45. Probenecid 68%
46. Rehabilitation 21%
47. Secondary Parkinson Disease 43%
48. Smoke 26%
49. Traumatic Brain Injury 81%
50. Wounds and Injuries 23%